ScreenerHero

INDP Indaptus Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · indaptusrx.com
2.260USD-12.74%Mkt Cap: 301.13M $P/E: —

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to pr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap301.13M USD
Enterprise Value333.54M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-20.85M USD
Revenue/Share—
Last Price2.260 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.86
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B30.47
EPS (TTM)-6.30
EPS (Forward)-1.39
52W Range
0.920018% of range8.570
52W High8.570 USD
52W Low0.9200 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-661.54%
ROA-223.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.82M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-3.21%
Net Debt-11.55M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio19.48
Quick Ratio18.77
Book Value/Sh0.09 USD
Cash/Share0.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateOct 30, 2020
Splits
Last Split1:28
Split DateJun 27, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.133.24M
Float23.36M
Insiders82.41%
Institutions0.30%
Short Interest
Short Ratio0.5d
Short % Float2.23%
Short % Out.0.69%
Shares Short916.35K
Short (prev mo.)123.74K
Technical
SMA 501.965 (+15.0%)
SMA 2002.271 (-0.5%)
Beta0.97
S&P 52W Chg16.45%
Avg Vol (30d)1.13M
Avg Vol (10d)620.35K
Technical Indicators
RSI (14)46.1
MACD0.1146
MACD Signal0.2672
MACD Hist.-0.1525
BB Upper4.311 USD
BB Middle2.929 USD
BB Lower1.548 USD
BB Width94.30%
ATR (14)0.4330 USD
Vol Ratio (20d)0.39x